Identifying blood markers for malignant pancreatic lesions
Official title: Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
Run by Centre Hospitalier Universitaire de Besancon · NCT06397846 · Data updated 2026-11-12
This study is trying to find blood markers that can help tell the difference between cancerous and non-cancerous pancreatic growths in patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Besançon and 1 other locations) |
| Status | Recruiting |
| Started | December 11, 2024 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT06397846 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men and women aged 18 and older who are being monitored for benign pancreatic lesions.
✕Probably not a fit
Patients with a known malignant pancreatic tumor will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to identify plasma biomarkers that can differentiate between malignant and benign pancreatic lesions. By analyzing biological samples from patients with benign pancreatic conditions, the research seeks to develop a clinico-biological signature that enhances the diagnosis and treatment of pancreatic cancer. The study will initially focus on candidate biomarkers identified in preliminary work, with the possibility of exploring additional markers. The ultimate goal is to improve diagnostic accuracy and therapeutic management for patients at risk of pancreatic cancer.
Why it matters
Potential benefit: If successful, this study could lead to the development of a blood test that improves early detection and treatment of pancreatic cancer.
How similar studies have gone: Other studies have explored biomarkers for pancreatic cancer detection, but this specific approach focusing on the tumor stroma is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women ≥18 years * Patient followed for benign pancreatic lesions: chronic pancreatitis acute pancreatitis at a distance from the acute episode (\> 4 weeks) with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN, TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas) Exclusion Criteria: * Malignant pancreatic tumor * Legal incapacity or limited legal capacity
Where it's running
-
University Hospital of Besancon
Besançon, France Recruiting -
Hôpital Nord Franche-Comté
Montbéliard, France Recruiting
Study contacts
- Study coordinator: Angélique VIENOT, Dr
- Email: a3vienot@chu-besancon.fr
- Phone: +3381479999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Severe chronic urticaria not responding to high-dose omalizumab in France
This study looks at adults with chronic spontaneous or inducible urticaria who don’t respond to optimized omalizumab to see what factors are linked to non-response and what other options people use.
-
Use of extracorporeal photopheresis in kidney transplant recipients with antibody-mediated rejection
This study looks at kidney transplant patients who had antibody-mediated rejection and were treated with extracorporeal photopheresis to see how they fare over a year.
-
See if VExUS ultrasound can guide fluid decisions in ICU patients with venous congestion
We’re testing whether a bedside ultrasound score (VExUS) helps doctors in the ICU decide how much IV fluid to give to adults with venous congestion.
-
How video games affect sleep in adult gamers without gaming disorder
This project will try methods to measure how playing video games affects sleep in adults who play regularly and in people who rarely play.
-
MP0317 plus gemcitabine‑cisplatin and durvalumab for first-line advanced biliary tract cancer
This trial will test whether adding MP0317 to gemcitabine–cisplatin plus durvalumab helps people with unresectable or metastatic biliary tract cancer stay progression-free at 12 months.
-
Femoral versus radial arterial pressure monitoring during cardiac surgery
This trial tests whether femoral arterial catheters give more accurate continuous blood pressure readings than radial catheters in adults undergoing cardiac surgery with cardiopulmonary bypass.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.